Once again, it is crucial to recognize outdated information presented here when the FDA has later acted to prevent severe consequences from misuse of approved medications. The antidotes for anticoagulants preventing blood clots from A-fib -- especially Coumadin, Andexxa, and Praxbind -- are vital examples.

The Harvard Health letter speaking highly of Andexxa was dated September 1, 2018; it reported initial approval of the drug on May 3, 2018. Two months later (December 31, 2018), the FDA modified its approval. It removed edoxaban (Savaysa) from the anticoagulants that Andexxa may be used against. The package insert and prescribing instructions also were modified (see <https://www.fda.gov/media/113279/download&gt;.

Praxbind, initially approved in October 2015, has undergone two important modifications, most recently on February 11, 2022, when the FDA approved special treatment for wrong-dose errors. The earlier change in April 2018 dealt with dosage and administration problems.

Take notice also that Andexxa and Praxbind are to be given only by intravenous injection. Coumadin (Warfarin) is neutralized by Vitamin K which can also be taken by mouth.

@rubywitch67 gives great advice above: "(D)on't take ANYTHING without discussing it with your doctor first!" They are up to date on safety of prescription drugs. I'll add my personal advice that, in getting treatment for bleeding injuries, ask the medical facility if they have the antidote on hand that you'll need to neutralize your chosen anticoagulant.